Related Experiment Videos
[Treatments of acute myocardial infarction other than recanalization ]
1Service de cardiologie A, Centre hospitalier universitaire de la Timone, Marseille.
Insights
In-hospital mortality from acute myocardial infarction has decreased due to intensive coronary care and reperfusion therapies. Standard care and medications like beta-blockers or ACE inhibitors also aid in reducing mortality and morbidity.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Acute myocardial infarction (AMI) management has evolved significantly over the last 15 years.
- In-hospital mortality rates for AMI have seen a considerable decline.
Purpose:
- To review the key factors contributing to the reduced mortality in acute myocardial infarction patients.
- To highlight essential general care measures and pharmacological interventions.
Summary:
- The decline in AMI mortality is attributed to intensive coronary care units and reperfusion strategies (thrombolysis, angioplasty).
- Essential general care includes close supervision, rest, diet modification, pain relief, anxiety reduction, oxygen therapy, and anticoagulation (heparin, aspirin).
- Pharmacological options such as beta-blockers and angiotensin-converting enzyme inhibitors are available to further reduce mortality and morbidity, though combined benefits require further study.
Impact:
- Improved patient outcomes and survival rates for acute myocardial infarction.
- Provides a comprehensive overview of current best practices in AMI management.
- Guides clinical decision-making regarding the choice of pharmacological therapy based on patient status.
Abstract:
During the past 15 years, the in-hospital mortality of patients with acute myocardial infarction has considerably declined. The 2 main reasons for this decrease in mortality have been the introduction of intensive coronary care units, and reperfusion of myocardial infarction, either by coronary thrombolysis or percutaneous transluminal coronary angioplasty. However benefits of other therapies should not be overlooked. General care measures should include: close supervision, bed rest, liquid diet, analgesics, reduction of anxiety, oxygen therapy, intravenous heparin and aspirin, monitoring of blood pressure and heart rate. beta-blockers and angiotensin-converting enzyme inhibitors, combined or not with thrombolytic therapy, are also available to reduce the rate of mortality and morbidity. The benefits to be expected from these 2 medications combined have not yet been demonstrated, so that it appears reasonable in common practice to choose either drug according to the patient's functional state.